353242-48-5

Upstream product

• 90945-66-7 3-(4-methoxy-2-nitrophenyl)acrylic acid 
• 22996-21-0 4-methoxy-2-nitro-benzaldehyde 
• 17484-36-5 4-Methyl-3-nitroanisole 
• 96-96-8 4-methoxy-2-nitroaniline 
• 58755-70-7 1-iodo-4-methoxy-2-nitrobenzene 
• 103986-96-5 methyl (E)-3-(4′-methoxy-2′-nitrophenyl)acrylate 

Downstream Products

• 353242-49-6 (2S,3S)-3-(4-methoxy-2-nitrophenyl)-2,3-epoxypropanol 
• 1050503-76-8 3-(4-methoxy-2-nitrophenyl)propan-1-ol 
• 1050514-09-4 5-methoxy-2-[3-(methylsulfonyl)propyl]aniline hydrochloride 
• 1050514-08-3 tert-butyl 5-methoxy-2-[3-(methylsulfonyl)propyl]phenylcarbamate 
• 1050514-07-2 tert-butyl 5-methoxy-2-[3-(methylthio)propyl]phenylcarbamate 
• 1050513-77-3 C₁₁H₁₅NO₆S 
• 1050513-78-4 3-(4-methoxy-2-nitrophenyl)-N,N-dimethylpropan-1-amine 
• 1050514-06-1 5-methoxy-2-[3-(methylthio)propyl]aniline 

Relevant academic research and scientific papers

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Asymmetric Synthesis of Functionalized 1,2,3,4-Tetrahydroquinolines

Highly enantioselective rhodium-catalyzed asymmetric hydrogenation (>98% ee) and Sharpless epoxidation (>90% ee) of o-nitrocinnamyl substrates lead to intermediates that can be transformed into tetrahydroquinoline derivatives. Starting materials are produced in high-yielding Heck reactions of an o-nitroaryl iodide and α-acetamidoacrylate or methyl acrylate.